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Background: Transcatheter aortic valve implantation (TAVI) is now considered the gold standard treatment of patients with severe symptomatic 
aortic stenosis (AS), ineligible for surgery. Bicuspidy is regarded as a relative contraindication to TAVI due to the risk of uneven expansion of the 
bioprosthesis. The purpose of this study was to evaluate the efficacy and safety of TAVI in patients with Bicuspidy.
Methods: Among 418 patients included in our prospective TAVI database (October 2006 to September 2011) 170 consecutive patients 
undergoing CT-scan were analyzed. We compared clinical outcomes in patients with vs. without bicuspidy.
Results: In our series, a bicuspid valve was found by CT scan in 14 patients (8.2%). Type 0 was found in 0%, 1 (L-R) in 92.9% and 2 (L-R+R-P) 
in 7.1%. Patients were 83.1±6.4 years old and EuroSCORE 20.3±10.4%. The bicuspid group was similar to the non bicuspid group except for 
diabetes (0 vs 23.1%, p=0.031) and coronary artery disease (28.6 vs 58.3%, p=0.031). Aortic annulus diameter was similar by TEE (22.8±2.2 vs 
22.3±1.9mm, p=0.391) and by CT-scan (24.3±3.2 vs 23.5±1.9mm, p=0.193). CoreValve was used more frequently in the bicuspid group (35.7 vs 
12.8%, p=0.036) and there was a trend towards higher incidence of pacemaker requirement in the bicuspid group (21.4 vs 7.1%, p=0.094) and 
all 3 patients in the bicuspid group received a CoreValve. There was no significant difference in device success (100 vs 93.6%, p=0.413), annulus 
rupture (0 vs 1.3%, p=0.841), valve migration (0 vs 1.3%, p=0.841) or coronary occlusion (7.1 vs 1.9%, p=0.293) in the bicuspid vs non bicuspid 
group respecteively. Post-procedural mean pressure gradient (10.2±3.3 vs 10.1±4.0mmHg, p=0.910) and aortic regurgitation ≥2/4 (14.3 vs 17.9%, 
p=0.732). No significant difference was observed in 30-day mortality (7.1 vs 8.3%, p=0.676) and 30-day combined safety point (21.4 vs 13.5%, 
p=0.314). Hospital stay was shorter in the bicuspid group (8.2±3.6 vs 11.9±6.4, p=0.037).
Conclusions: In patients with bicuspid AS, TAVI can be performed with a low complication rate with similar efficacy and acceptable outcomes as in 
patients without bicuspidy.
